To evaluate the role of chemotherapy and/or rituximab for treatment of posttransplant lymphoproliferative disorder (PTLD) in solid organ transplantation.
Data Sources:
A MEDLINE search (1966–May 2007) was conducted using the key words posttransplant lymphoproliferative disorder, solid organ transplantation, chemotherapy, and rituximab. References of relevant articles and abstracts from recent hematology, oncology, and transplantation scientific meetings (2004–May 2007) were also reviewed.
Study Selection and Data Extraction:
Prospective and retrospective studies identified from the data sources were evaluated, and all information deemed relevant was included for this review.
Data Synthesis:
Overall response rates ranged from 53% to 68%, 25% to 83%, and 74% to 100% for rituximab monotherapy, chemotherapy, and chemotherapy plus rituximab, respectively. Positive response to treatment was influenced by prognostic factors, including presence of Epstein-Barr virus in tumor cells, normal lactate dehydrogenase levels, good performance status, early disease onset after transplantation, and early disease stages. These factors in study patients likely contribute to the variability in response rates seen between treatment options. Severe adverse effects, ranging from grade 3 neutropenia to infection resulting in death, occurred more frequently in patients receiving chemotherapy than in patients receiving only rituximab.
Conclusions:
Although reduction in immunosuppressive medications remains the first-line therapy for PTLD treatment, many cases do not respond to this treatment alone, especially monomorphic or more aggressive cases of lymphoma. Therefore, it is reasonable to begin active treatment including rituximab and/or chemotherapy initially, along with reduction in immunosuppression in many cases. Further prospective, comparative studies are urgently needed to confirm the efficacy of these treatment strategies as well as to clarify which subset of patients may benefit most from them.
GottschalkS, RooneyCM, HeslopHE. Posttransplant lymphoproliferative disorders. Annu Rev Med2005;56:29–44.
2.
SokalEM, AntunesH, BeguinC, . Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation1997;64:1438–42.
3.
WalkerRC, PayaCV, MarshallWF, . Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant1995;14:214–21.
4.
ShahinianVB, MuirheadN, JevnikarAM, . Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation2003;75:851–6.
5.
DottiG, FiocchiR, MottaT, . Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation2000;69:827–33.
6.
TsaiDE, HardyCL, TomaszewskiJE, . Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001; 71:1076–88.
JainAB, MarcosA, PokharnaR, . Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation2005;80:1692–8.
9.
MilpiedN, VasseurB, ParquetN, . Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol2000;11:113–6.
10.
ChoquetS, LeblondV, HerbrechtR, . Efficacy and safety of rituximab in B cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood2006;107:3053–7.
11.
OertelSK, VerschuurenE, ReinkeP, . Effect of anti-CD20 antibody rituximab in patients with post transplant lymphoproliferative disorder. Am J Transplant2005;5:2901–6.
12.
BlaesA, PetersonB, BarlettN, . Rituximab therapy is effective for post transplant lymphoproliferative disorders after solid organ transplantation. Cancer2005;104:1661–7.
13.
GrossTG, BucuvalasJC, ParkJR, . Low-dose chemotherapy for Epstein-Barr virus-positive posttransplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol2005;23:6481–8.
14.
FohrerC, CaillardS, KoumarianouA, . Long-term survival in posttransplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol2006;134:602–12.
15.
ChoquetS, TrappeR, LeblondV, JagerU, DaviF, OertelS.CHOP-21 for the treatment of posttransplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica2007;92:273–4.
16.
OertelSH, Papp-VaryM, AnagnostopoulosI, HummelMW, JonasS, RiessHB. Salvage chemotherapy for refractory or relapsed posttransplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol2003;123:830–5.
17.
BuellJF, GrossTG, HanawayMJ, . Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc2005;37:956–7.
18.
Mamzer-BruneelMF, LomeC, MorelonE, . Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol2000;18:3622–32.
19.
TrappeR, OertelS, ChoquetS, LeBlondV, Papp-VaryM, RiessH.Sequential treatment with the anti-CD 20 antibody rituximab and CHOP+GCSF chemotherapy in patients with posttransplant lymphoproliferative disorder (PTLD): first interim analysis of a multicenter phase II study (abstract). Blood (ASH Annual Meeting Abstracts)2005;106:932
20.
OrjuelaM, GrossTG, CheungYK, . A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with posttransplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res2003; 9(suppl 10 pt 2):3945S–52S.
21.
ElstromRL, AndreadisC, AquiNA, . Treatment of PTLD with rituximab or chemotherapy. Am J Transplant2006;6:569–76.
22.
TaylorAL, BowlesKM, CallaghanCI, . Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation2006;82:375–81.
23.
TulpuleS, MikhaeelG, KazmiM, . B cell post transplant lymphoproliferative disorder complicating solid organ transplantation (B-PTLD): a single centre review reporting 1) Results with chemo-immunotherapy (CHOP/R) and 2) the predictive ability of FDG-PET scanning to correlate with long term overall survival (abstract). Blood (ASH Annual Meeting Abstracts)2005;106:1500.
24.
JainA, NalesnikM, ReyesJ, . Post transplant lymphoproliferative disorder in liver transplantation. A 20-year experience. Ann Surg2002;236:429–37.
25.
BagotCN, KulasekararajA, RamalingamS, . Outcome of lymphoproliferative disorder in liver transplant recipients may correlate with age at diagnosis and the use of chemotherapy: a single centre report (abstract). Blood (ASH Annual Meeting Abstracts)2005;6:1435.
26.
BenkerrouM, JaisJP, LeblondV, . Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood1998;92:3137–47
27.
GhobrialIM, HabermannTM, MaurerMJ, . Prognostic analysis for survival in adult solid organ transplant recipients with posttransplantation lymphoproliferative disorders. J Clin Oncol2005;23:7574–82.
28.
LeblondV, SuttonL, DorentR, . Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol1995;13:961–8.
CoiffierB, LepageE, BriereJ, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med2002;346:235–42.
31.
PfreundschuhM, TrumperL, OsterborgA, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol2006;7:379–91.
32.
EBPG Expert Group on Renal Transplantation.European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Posttransplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant2002;17:31-3, 35–6.
33.
SmithTJ, KhatcheressianJ, LymanGH, . 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol2006;24:3187–205.
34.
Gafter-GviliA, FraserA, PaulM, LeiboviciL.Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med2005;142:979–95.
35.
Papp-VaryM, OertelSHK, MaschmeyerG, RiessH.Single dose per cycle pegfilgrastim successfully supports full dose CHOP-21 in patients with posttransplant lymphoproliferative disorders (PTLD) (abstract). Blood (ASH Annual Meeting Abstracts)2004;104:4591.
